Speakers
Dr. Nick Pliam joined Decheng Capital at its inception in 2011 and is based in its Menlo Park office. Trained as an orthopedic surgeon and…
Read MoreBarbara Wirostko MD, a serial entrepreneur, is the CMO and Co-founder of Qlaris Bio as well as Co-founder and Medical Advisor to MyEyes. As a…
Read MoreDr. Heah is an accomplished executive who brings over two decades of drug development and commercial experience, focused primarily in gene therapy and ophthalmology. She…
Read MoreProfessor of Ophthalmology, Vice Chair of International Research and Academic Affairs, Director of Ophthalmic Vascular Diagnostic & Research Program at Mount Sinai Hospital, Icahn School…
Read MoreDr. Navratil has served as our chief development officer since April 2022. He previously served as our senior vice president, research and development since joining…
Read MoreAbla Creasey is the Vice President of Therapeutics Development. In this capacity, she leads all programs in Translational and Clinical development, with a focus on…
Read MoreRetinal specialist with both extensive basic science training, clinical trial experience and drug development experience in Big Pharma. Main research interest is macular diseases, including…
Read MoreDr. Sherif joined Oculis as CEO in 2017 from Novartis where he served as Entrepreneur in Residence at the Novartis Venture Fund and since 2022,…
Read MoreHannah H. Chang is a Managing Director at Platanus, a global evergreen investment fund. Dr. Chang leads the firm’s healthcare venture capital strategy, investing in…
Read MoreMark L. Baum is the founder, Chairman of the Board, and CEO of Harrow. For the 2014-2017 periods, Harrow (formerly Imprimis Pharmaceuticals) was named by…
Read MoreDr. Frank W. Bowden, III, is the founder of Bowden Eye & Associates, a successful integrated eye care practice which he established in Jacksonville, Florida…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.